Clinical trials: Viral Shedding
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
On 13 August 2008, this trial was submitted to ClinicalTrials.gov as modification to NCT00362297. On 28 April 2011, the two records were split for administrative purposes and each trial was given its own unique study record.
- Trial name
- NCT01346475
- Testing
- valacyclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Herpes Simplex Type 2
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
The purpose of this study is to evaluate the effect of recombinant human heat shock protein 70-polyvalent peptide complex (HerpV) vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before…
- Trial name
- NCT01687595
- Testing
- HerpV and QS-21
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Agenus Inc.
SARS-CoV 2
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction…
- Trial name
- NCT04405739
- Testing
- EIDD-2801
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Ridgeback Biotherapeutics, LP
Herpes Labialis
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
- Trial name
- NCT00306293
- Testing
- valacyclovir
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Genital Herpes
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and are HSV-2 seropositive and…
- Trial name
- PK/GUD (NCT00808405)
- Testing
- acyclovir
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Washington
Healthy
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
Primary objective of this study is to describe the safety and tolerability of multiple doses of MEDI-534 in children 6 to less than (<) 24 months of age and in infants 2 months of age.
- Trial name
- NCT00686075
- Testing
- MEDI-534, Cohort 1, MEDI-534, Cohort 2, MEDI-534, Cohort 3
- Where
- 100 sites in United States, Australia and 7 more
- Volunteers
- 1,338 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Avian Influenza
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths…
- Conditions
- Influenza, Avian Influenza, Severe Influenza
- Trial name
- NCT00298233
- Testing
- Oseltamivir
- Where
- 12 sites in Singapore, Thailand and 1 more
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Viral Infections, Respiratory Syncytial Virus Infections
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
The overall objective of the MEDI-534 clinical development program is to evaluate the safety, efficacy and tolerability of MEDI-534 for the prevention of serious RSV and PIV3 disease in young infants.
- Conditions
- Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
- Trial name
- CP149 (NCT00493285)
- Testing
- MEDI-534
- Where
- 30 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
CMV, Congenital Cmv
Cytomegalovirus Shedding Characteristics in Pregnant Women
The cCHIPS study is a feasibility study for larger scale multi-centre studies and is designed as a single-centre observational cohort, longitudinal, natural history study.
- Conditions
- CMV, Congenital Cmv, Maternal Infections Affecting Fetus or Newborn, Shedding Virus
- Trial name
- cCHIPS (NCT04021628)
- Testing
- No intervention- not applicable
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- St George's, University of London
Healthy
A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age
The primary objective of this study is to describe the safety and tolerability of 3 doses of MEDI-560 at 10^5 TCID50 when administered to children 6 to < 12 months of age who are HPIV3 (human parainfluenza virus type 3)…
- Trial name
- NCT00508651
- Testing
- MEDI-560
- Where
- 23 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID-19
Niclosamide for Mild to Moderate COVID-19
This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04399356
- Testing
- Niclosamide, Telehealth monitoring
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Tufts Medical Center
Upper Respiratory Tract Infections, Virus
Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)
ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard care in participants with clinically suspected…
- Conditions
- Upper Respiratory Tract Infections, Virus, COVID, Virus Shedding
- Trial name
- NCT04382131
- Testing
- NaCl Solution
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Edinburgh
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
The purpose of the research study is to evaluate the effectiveness of high-dose acyclovir compared to valacyclovir for reduction of asymptomatic genital shedding in persons with genital herpes.
- Trial name
- NCT00362297
- Testing
- acyclovir, valacyclovir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Washington
Human Immunodeficiency Virus, Virus Shedding
The Compartmental Biology of HIV in the Male Genital Tract
Male participants taking tenofovir-emtricitabine (TDF/FTC) will provide semen and blood samples which will be analyzed to better understand the pharmacology of antiretroviral therapy in the male genital tract.
- Trial name
- NCT02638493
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Poliomyelitis
Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
The purpose of this study is to assess the safety (primary objective), the ability to trigger the production of antibodies (immunogenicity; a secondary objective) and presence of vaccine virus in the stool (fecal shedding; a…
- Trial name
- NCT04529538
- Testing
- Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)
- Where
- 4 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- PATH
Rotavirus Infection, Vaccine Response Impaired
The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity
Rotavirus is the leading cause of diarrhea in children worldwide. Oral rotavirus vaccines work remarkably well in high-income countries, but for unclear reasons they underperform in low-income countries.
- Conditions
- Rotavirus Infection, Vaccine Response Impaired, Vaccine Virus Shedding
- Trial name
- NCT02992197
- Testing
- Rotarix, dose 1, Rotarix, dose 2
- Where
- Bangladesh
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Bacterial Vaginosis
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
This investigation assessed the effects of asymptomatic BV on daily genital tract shedding of HSV-2 by determining shedding frequency before and after treatment of asymptomatic BV.
- Trial name
- MASH (NCT00464542)
- Testing
- Metronidazole
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Herpes Simplex Virus
Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture
PCR detection of HSV DNA shedding in the female genital tract using the GeneXpert system (Cepheid, Sunnyvale CA) will be compared with traditional (routine) PCR (pregnant and nonpregnant women) and with HSV culture (nonpregnant…
- Trial name
- NCT01878383
- Testing
- Genexpert assay
- Where
- 15 sites in United States
- Volunteers
- 12,550 people
- Sponsor
- University of Alabama at Birmingham
Influenza Vaccines
Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
LAIV shedding studies in children could be an important way to confirm whether impediments to viral replication do indeed explain these observed reductions in vaccine effectiveness (VE), whether prior vaccination has any…
- Trial name
- FluSHED-2 (NCT03735147)
- Testing
- Live attenuated influenza vaccine (LAIV)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
SARS-CoV-2 Infection
A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.
- Trial name
- CoVPN 3006 (NCT04811664)
- Testing
- Moderna COVID-19 Vaccine
- Where
- 51 sites in United States
- Volunteers
- 1,923 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)